Spectrum Pharmaceuticals (NASDAQ:SPPI) shareholders got some great news when Spectrum Pharmaceuticals announced that the FDA approved its drug Beleodaq five weeks before its scheduled PDUFA date. But the stock dropped anyway -- 3% by the end of the day -- after some gains in pre-market.

The big question investors are asking now, of course, is what this approval means for Spectrum. In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give their take on the news and the stock.